{
    "name": "methylnaltrexone",
    "comment": "Rx",
    "other_names": [
        "Relistor"
    ],
    "classes": [
        "Peripherally-Acting Mu-Opioid Receptor Antagonists (PAMORA)"
    ],
    "source": "https://reference.medscape.com/drug/relistor-methylnaltrexone-342081",
    "pregnancy": {
        "common": [
            "The limited available data with in pregnant women are not sufficient to inform a drug-associated risk for major birth defects and miscarriages; there are clinical considerations when drug is used by pregnant women; advise pregnant women of potential risk to a fetus",
            "Use during pregnancy may precipitate opioid withdrawal in a fetus due to immature fetal blood-brain barrier"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "No information regarding presence of methylnaltrexone in human milk, effects on breastfed infant, or on milk production; methylnaltrexone is present in rat milk; because of potential for serious adverse reactions, including opioid withdrawal, in breastfed infants, advise women that breastfeeding is not recommended during treatment"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Documented hypersensitivity",
                "Known or suspected GI obstruction and patients at increased risk of recurrent obstruction"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Discontinue if severe/persistent diarrhea develops",
                "GI perforation reported with other PAMORA in patients with conditions associated with reduced structural integrity in the wall of the GI tract (eg, PUD, Ogilvie syndrome, diverticular disease, infiltrative GI malignancies, peritoneal metastases, Crohn disease); monitor for development of severe, persistent, or worsening abdominal pain; discontinue naloxegol in patients who develop these symptoms",
                "Symptoms consistent with opioid withdrawal (eg, hyperhidrosis, chills, diarrhea, abdominal pain, anxiety, irritability, yawning) reported; monitor for symptoms of withdrawal in such patients",
                "Therapy administration for longer than four months not studied; discontinue therapy when opioid therapy has ended",
                "Use with caution in hepatic or renal impairment; dosage adjustments necessary"
            ],
            "specific": []
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Abdominal pain",
            "percent": "28.5"
        },
        {
            "name": "Flatulence",
            "percent": "13.5"
        },
        {
            "name": "Nausea",
            "percent": "11.5"
        },
        {
            "name": "Dizziness",
            "percent": "7.3"
        },
        {
            "name": "Hyperhidrosis",
            "percent": "6.7"
        },
        {
            "name": "Diarrhea",
            "percent": "5.5"
        },
        {
            "name": "Gastrointestinal",
            "percent": null
        },
        {
            "name": "Cramping",
            "percent": null
        },
        {
            "name": "perforation",
            "percent": null
        },
        {
            "name": "vomiting",
            "percent": null
        },
        {
            "name": "General disorders and administrative site disorders",
            "percent": null
        },
        {
            "name": "Diaphoresis",
            "percent": null
        },
        {
            "name": "flushing",
            "percent": null
        },
        {
            "name": "malaise",
            "percent": null
        },
        {
            "name": "pain",
            "percent": null
        }
    ]
}